Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629772 | 0.83 | KMT2A (0.38) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6627669 | 0.83 | MEN1 (0.38) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6628966 | 0.82 | MAPT (0.39) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6628991 | 0.81 | MEN1 (0.37) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6627640 | 0.81 | MAPT (0.43) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6627909 | 0.80 | MAPT (0.44) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6628087 | 0.80 | MEN1 (0.36) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6628929 | 0.79 | GAA (0.38) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL6628094 | 0.79 | MAPT (0.39) | MEN1KMT2AGFERGAAMAPT | |
| SCHEMBL8680379 | 0.79 | MAPT (0.57) | MEN1KMT2AGFERGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299391-B1 | INDOLINOSPIROPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | JOHNSON & JOHNSON VISION CARE (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6803471-B2 | USEFUL AS PHOTOCHROMIC COMPOUNDS; COVALENTLY ATTACHED TO WANG RESINS AND METHOD OF ATTACHING; OPHTHALMIC LENSES | JOHNSON & JOHNSON VISION CARE, INC. | 2004-10-12 | — | — | US | disclosed |
| US-6521753-B1 | Indolinospiropyran compounds and methods for their manufacture | JOHNSON & JOHNSON VISION CARE, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020087010-A1 | Indolinospiropyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087010-A1 | Indolinospiropyran compounds and methods for their manufacture | DHPS, IDO1, INMT | MEN1 3140/4885KMT2A 2464/4885GFER 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.